Abstract


Close Window



Table 1: Baseline characteristics

London (N=30)

NINDS treated
(p-value) (N=168)

NINDS placebo
(p-value) (N=165)

Mean age, (y+/-SD)

70+/-10

69+/-12

66+/-13 (<0.1)

Female (%)

63

43

42

White (%)

100

69

66

Baseline NIHSS (median)

14

14

15

Treated at 0-90 minutes (%)

3

51 (0.000001)

47 (0.000007)

Treated at 91-180 minutes (%)

90

49

53

Treated at 181-195 minutes

7

0

0

Hypertension (%)

60

67

67

Smoking (%)

27

27

35

Prior stroke (%)

30

12

9

Diabetes (%)

20

20

20

Coronary disease (%)

30

22

20

Atrial fibrillation (%)

17

20

16

Anti-platelet use (%)

37

40

26

Suspected lacunar syndrome (%)

17

14

9

 

Table 2: Outcomes

London % (N=30)

NINDS treated % (p-value)* (N=168)

NINDS placebo % (p-value)* (N=165)

24 hours

4 point improvement or normal

63

48 (0.11)

39 (0.02)

Three months

NIHSSS

0-1

37

31 (0.46)

20 (0.03)

2-8

43

30

32

>8

7

22

27

Death

13

17

21

death or severe disability

20

39 (0.04)

48 (0.004)

modified Rankin

0-1

37

39 (0.79)

26 (0.23)

2-3

37

21

25

4-5

13

23

27

Death

13

17

21

death or severe disability

27

40 (0.15)

48 (0.03)

NIHSSS= National Institute of Health Stroke Scale score.
Severe disability is defined as an NIHSSS > 8 or modified Rankin score equal to 4 or 5.
*All statistical comparisons are made in reference to the London group.

 

Table 3: Complication rates

London % (N=30)

NINDS treated % (N=312)

NINDS placebo % (N=312)

Symptomatic ICH

0

6.4

0.6

Fatal ICH

0

2.9

0.3

Asymptomatic ICH

3.3

4.5

2.9

Petechial hemorrhage

23.3

NA

NA

Major systemic hemorrhage

3.3

1.6

0

ICH = intracranial hemorrhage: NA = not available: p>0.05 for all comparisons to London group

 


 
For information about this web site e-mail to:
Copyright © Canadian Journal of Neurological Sciences. All rights reserved.